Development of a stable liquid formulation of live attenuated influenza vaccine

July 12, 2016 – Development of a stable liquid formulation of live attenuated influenza vaccine (full text) “In conclusion, this paper describes the successful identification of stable liquid LAIV formulations for use in seasonal vaccination programs. A liquid LAIV formulation allows for a vaccine that is easier to use, potentially leading to greater acceptance and wider adoption of seasonal vaccination. Through this process, we identified a liquid formulation consisting of sucrose phosphate glutamate buffer with 1% arginine and 0.5% recombinant human serum albumin that provided storage stability of one year at 2–8 °C for the influenza A and B strains tested.

Read more here: Vaccine Research Library

Please follow and like us:

Related Post

Leave a Reply